Bronchogen Nitrogenous Bases Price

Direct Assessment: Bronchogen and Nitrogenous Bases Research Pricing

The pricing of research-grade Bronchogen in combination with nitrogenous base reference standards typically ranges depending on lyophilized purity levels, mass spectrometry validation, and endotoxin thresholds. Laboratory-grade Bronchogen (Ala-Asp-Glu-Leu) synthesized at greater than 98% purity commands a premium due to required RP-HPLC purification and lot-specific verification, with institutional tier discounts available for bulk research orders.

When purchasing compounds for cellular or molecular research, evaluating the price per milligram requires looking beyond the raw cost to inspect the analytical documentation included with every lot. Substandard peptides with unverified nitrogenous base interactions or high impurity levels increase experimental variance and compromise data integrity. Sourcing high-purity peptides directly from a USA-based manufacturer like PX1 Research ensures traceable chemical identity, low endotoxin levels, and consistent batch-to-batch stoichiometry necessary for valid quantitative bioassays.

Biochemical Structure and Properties of Bronchogen

Bronchogen is a synthetic tetrapeptide with the amino acid sequence L-Alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu). Derived from short-chain peptide research initially pioneered in bioregulatory peptide studies, Bronchogen is designed to target chromatin structures and modulate gene expression within bronchial and epithelial cell lines in vitro.

The small molecular size of Bronchogen allows researchers to investigate peptide-nucleic acid interactions at the molecular level. Due to its short sequence length, high-throughput chemical synthesis must maintain strict optical purity to prevent D-amino acid racemization during peptide coupling. Researchers examining peptide sequences across our comprehensive catalog of research peptides often analyze how specific acidic amino acid side chains (such as Aspartate and Glutamate) interact with histone proteins and DNA double helices.

Molecular Interaction Between Short Peptides and Nitrogenous Bases

A central focus of preclinical peptide research involves how short regulatory peptides interact with nitrogenous bases—adenine, guanine, cytosine, thymine, and uracil. In vitro studies demonstrate that short peptide sequences can penetrate cell membranes and intercalate into the major and minor grooves of double-stranded DNA or bind directly to specific base pairs.

Preclinical data suggest that the carboxyl and amide groups on short peptides like Bronchogen form hydrogen bonds with the functional groups of nitrogenous bases within chromatin. This chemical association is hypothesized to alter local DNA conformation, promoting accessibility for transcription factors or modifying epigenetic expression profiles. Understanding these fundamental binding dynamics provides crucial context when evaluating research library hub documentation on peptide-gene regulatory networks.

Preclinical Literature and Respiratory Epithelium Studies

In vitro and animal model studies have evaluated Bronchogen for its role in modulating respiratory tissue function and bronchial epithelial integrity. In cell culture models subjected to oxidative stress or inflammatory signaling molecules, short regulatory peptides have been observed to influence the expression of mucin genes, pro-inflammatory cytokines, and surfactant proteins.

In rodent models of pulmonary hyperreactivity, researchers observed that administration of short regulatory sequences altered mRNA expression profiles corresponding to tissue repair cascades. These experiments suggest that peptide-mediated DNA interactions may trigger downstream transcriptomic shifts without causing genomic mutation. However, these effects remain strictly within the domain of preclinical investigation, requiring controlled laboratory setups to measure precise protein expression and RNA sequencing outputs.

Factors Influencing Synthesis Costs and Price Differences

The price of research-grade Bronchogen and nitrogenous base assay reagents is governed by several critical manufacturing and quality control variables:

1. Purity Thresholds: Reaching a purity of ≥98% via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) requires multiple purification passes, reducing total yield but eliminating truncated or side-reaction peptide impurities.

2. Analytical Validation: Comprehensive quality assurance requires both mass spectrometry (LC-MS) for molecular weight confirmation and RP-HPLC for chemical purity determination.

3. Endotoxin Testing: For cell culture work, endotoxins must be rigorously measured (typically <0.01 EU/mg) using Chromogenic LAL assays to prevent non-specific immune responses in cell assays.

4. Scale and Custom Packaging: Lyophilization into specific unit sizes (e.g., 10mg, 20mg vials) under inert argon gas shielding adds labor and equipment costs compared to unformulated bulk powder. Institutional laboratories purchasing in high volumes can access specialized pricing structures through wholesale lab accounts.

Comparative Analysis of Short Bioregulatory Peptides

Bronchogen belongs to a broader family of short bioregulatory peptides investigated for tissue-specific gene regulation and epigenetic modulation. Comparing Bronchogen to other short peptides helps researchers select the appropriate compound for their specific target tissue or receptor model.

In comparative preclinical models, while Bronchogen is primarily studied in respiratory and bronchial cell lines, Epitalon is evaluated for its interactions with telomerase activity and neuroendocrine regulation. Similarly, Vilon is studied for immune cell activation and chromatin remodeling, whereas Thymogen is utilized in immunomodulatory cellular assays. Each peptide demonstrates sequence-specific binding affinities for distinct chromosomal regions and nitrogenous base sequences.

Analytical Quality Standards and Verification at PX1 Research

To ensure reproducible experimental outcomes, PX1 Research enforces strict manufacturing and verification standards for every lot of peptide supplied to research institutions. Every product undergoes independent testing in an ISO 17025 accredited laboratory prior to release.

Researchers receive a lot-specific Certificate of Analysis (COA) containing raw RP-HPLC chromatograms, electrospray ionization mass spectrometry (ESI-MS) spectra, and endotoxin assay results. All compounds are synthesized in cGMP-compliant US facilities and stored under climate-controlled conditions. Orders placed before 12:00 PM PST ship the same business day from our distribution centers in California and Arizona, ensuring rapid, reliable delivery to maintain supply chain integrity for critical lab workflows.

Laboratory Reconstitution and Handling Guidelines

Proper reconstitution and storage procedures are essential to preserve the structural integrity of synthetic peptides like Bronchogen during laboratory trials. Lyophilized peptides should be stored at -20°C or -80°C in a dry environment away from light upon receipt.

Prior to opening the vial, allow the container to equilibrate to room temperature to prevent condensation from forming inside the vial. Reconstitute the dry peptide using sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) depending on the requirements of your in vitro assay. Avoid vigorous vortexing, as mechanical shear stress can disrupt peptide bonds; instead, gently swirl the vial until the solid is completely dissolved. Aliquot the reconstituted solution into single-use microcentrifuge tubes and freeze at -80°C to minimize freeze-thaw cycles.